Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Triptolide||C1572||Triptolide (C1572) is a plant-derived small molecule that reduces MYC protein expression, and may decrease cancer stem cell number and tumor growth (PMID: 28951456, PMID: 32775615).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||triple-receptor negative breast cancer||not applicable||Triptolide||Preclinical - Cell line xenograft||Actionable||In a preclinical study, treatment with Triptolide (C1572) decreased Myc protein expression, decreased cancer stem-like cell (CSC) number, and induced senescence in a triple-negative breast cancer (TNBC) cell line in culture, and depleted CSCs and reduced tumor growth in TNBC cell line xenograft models (PMID: 28951456).||28951456|
|Unknown unknown||gastric adenocarcinoma||not applicable||Triptolide||Preclinical - Cell culture||Actionable||In a preclinical study, treatment with Triptolide (C1572) induced apoptotic cell death and resulted in decreased cell viability in gastric adenocarcinoma cell lines in culture (PMID: 28192510).||28192510|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|